Conditions: Lymphoma, Non-Hodgkin's
Keywords: Celgene Revlimid CC-5013 Non-hodgkin's lymphoma Lenalidomide CC5013 NHL
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 217
Healthy volunteers: no

Brief summary:
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop

Detailed description:

Arms:
arm 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 days

Interventions: intervention 1: lenalidomide
Intervention descriptions: intervention 1: once daily oral capsule

Protocol document: